|
Indian
Pharma Industry Report
Introduction
The
Indian pharmaceutical industry grew at 13% during
2003-2007, driven by rising consumption levels in the
country and strong demand from export markets. In
2006-07, the Indian pharma market reached US$ 8.16
billion and is estimated to reach US$ 9.77 billion in
2007-08. At present, India’s pharmaceutical industry
constitutes 1-2% of the global pharmaceutical market in
value terms.
Key
Findings & Highlights
-
The
market is estimated to register sales of US$ 743
billion in 2008 with a growth of 5-6% compared with
6-7% in 2007.
-
In
2007, 71% of oncology product sales came from the US
and Europe’s top five markets—France, Germany,
Italy, the UK and Spain.
-
The
growth accelerates in the seven “pharmerging”
markets of China, Brazil, Mexico South
Korea, India, Turkey and Russia and is expected to
grow by 12–13% in 2008 to US$ 85–90 billion.
-
Generic
producing companies Barr, Ranbaxy, Mylan, Teva,
Actavis and Dr Reddy’s Labs
have become dominant as they keep launching more and
more generics.
-
In
world rankings, the Indian pharmaceutical industry
stood fourth in terms of volume and 13th in terms of
value in 2006-07.
-
Exports
are bifurcated into exports services comprising
contract manufacturing, contract research.
-
India
currently has more than 80 FDA-approved plants,
followed by Italy (55) and
China (27).
Your
Questions Answered
-
What
is the expected growth in the seven
“pharmerging” markets across the world?
-
What
is the % of product sales came from US &
Europe’s Top five markets?
-
What
are the primary growth drivers in pharma industry?
-
Why
companies are increasingly turning to licensing?
-
What
are the drugs dominated domestic retail pharma
market in 2007?
Clients
subscribed for
Pharmed
Ltd., Apex Labs Ltd, Vignan Jyothi Institute of Mgmt.,
Zim
Labs Ltd, Indian Immunologicals Ltd.
Why it
is a bestseller?
For
it’s in depth coverage, Content, Presentation in terms
of charts and tables.
New
Reports launched in Nov'08 are
-
QPAC-JAS
08
-
Nuclear
Energy Industry Insight
-
Pre
feasibility Report on Business School
-
Top
200 Pharma Companies Profile
|
